Phase II open-label study of sunitinib in patients with advanced breast cancer.
about
Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.Vasculotide reduces endothelial permeability and tumor cell extravasation in the absence of binding to or agonistic activation of Tie2.Cross-sectional study of Pfizer-sponsored clinical trials: assessment of time to publication and publication history.Receptor Tyrosine Kinase Expression Predicts Response to Sunitinib in Breast CancerInhibition of RET increases the efficacy of antiestrogen and is a novel treatment strategy for luminal breast cancer.Investigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapy.Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib.Apatinib for metastatic breast cancer in non-clinical trial setting: Satisfying efficacy regardless of previous anti-angiogenic treatment.Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy.
P2860
Q33413742-ECFE782C-9B3F-47A2-A4FE-1469722302E1Q35695381-287FBE9C-7C9D-495E-AC08-0D600A3A0E9EQ37133927-C84DD368-7111-454A-98DC-8F7BE2AFF3EAQ37214094-47A0D64D-1084-49DD-B9D3-34F40DC43B3EQ37707145-397513BB-10B5-49B0-B2BC-41D8F1BFDD60Q38193533-79255C25-434A-43E5-BC5B-1ED9DA8FDE1FQ38627885-F878F179-7D42-4B8F-A739-27E0673F51FEQ47339196-57209197-CAC0-4EAC-920A-52BF456CECE1Q54393339-F1FA14C7-16D7-40AA-B447-444B20587F6E
P2860
Phase II open-label study of sunitinib in patients with advanced breast cancer.
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Phase II open-label study of sunitinib in patients with advanced breast cancer.
@ast
Phase II open-label study of sunitinib in patients with advanced breast cancer.
@en
type
label
Phase II open-label study of sunitinib in patients with advanced breast cancer.
@ast
Phase II open-label study of sunitinib in patients with advanced breast cancer.
@en
prefLabel
Phase II open-label study of sunitinib in patients with advanced breast cancer.
@ast
Phase II open-label study of sunitinib in patients with advanced breast cancer.
@en
P2093
P2860
P1476
Phase II open-label study of sunitinib in patients with advanced breast cancer.
@en
P2093
Denise A Yardley
Dennis L Citrin
E Claire Dees
Jolanda Paolini
Kenneth A Kern
Marla J Brickman
Paul Healey
Stephen D Myers
Zhixiao Wang
P2860
P2888
P304
P356
10.1007/S10549-012-2285-0
P407
P577
2012-10-17T00:00:00Z
P6179
1033335591